BioSpace News Archive

Business

Why is the FDA Taking So Long to Review a COVID-19 Vaccine?

the robustness and independence of FDA review – even under an EUA – is an important factor in encouraging a skeptical public to accept COVID-19 vaccinations.

December 3, 2020
·
4 min read
·
Gail Dutton
Business

Better Together – Merck KGaA Announces Collaboration with Artios

Merck KGaA and Artios Pharma Limited announced today that they have entered a strategic collaboration agreement to discover and develop multiple precision oncology drugs over the course of the next three years.

December 3, 2020
·
3 min read
·
Krystle Vermes
Drug Development

COVID-19 Vaccine Frontrunners Still Largely Untested in Children

Children, who have not been widely tested in clinical trials for the vaccine, are typically less severely affected and are much further down the priority list for receiving the vaccines. But the vaccine has not been tested at all in younger children.

December 3, 2020
·
4 min read
·
Mark Terry
Career Advice

The 15 Most Common Questions Asked in an Interview

While you’ve likely answered many of these before, it never hurts to brush up on solid answers and think of new or recent anecdotes to illustrate your point.

December 3, 2020
·
1 min read
·
Laura Brothers
Policy

Daily Rundown: Who’s Gunning For and Gaining Approval and Other Industry News

Check out some news happening today around the biopharma industry.

December 3, 2020
·
4 min read
·
Alex Keown
BioForest

Biotech Boom Continues – Silverback Ups IPO Raise to $195 Million

Upping the numbers two times, Silverback now readies a 10 million share offering.

December 3, 2020
·
2 min read
·
Kate Goodwin
Genetown

Record-High Growth Has Merck Cashing in on Moderna

Moderna’s stock has boomed over the course of 2020, and Merck is cashing in.

December 3, 2020
·
2 min read
·
Alex Keown
Policy

Critics’ Opinions Roll In as UK Approves COVID-19 Vaccine

Yesterday, the United Kingdom’s MHRA granted temporary authorization for emergency use to Pfizer and BioNTech for their COVID-19 mRNA vaccine. It didn’t take long for the decision to generate criticism and questions.

December 3, 2020
·
4 min read
·
Mark Terry
BioCapital

AstraZeneca Most Recent Victim of Hackers Posing as Recruiters

As if attempting to steal hard-won research wasn’t bad enough, hackers are now hitting people where it really hurts – with e-documents containing malicious code embedded in false offers of employment.

December 3, 2020
·
4 min read
·
Heather McKenzie
Drug Development

Despite Failure to Meet Phase III Primary Endpoint, Jazz’s SCLC Drug Holds Promise

While promising, the study showed no difference between this combination regimen and physician’s choice of topotecan or cyclophosphamide/doxorubicin/vincristine (CAV) in terms of overall survival (OS).

December 3, 2020
·
3 min read
·
Brandon May